MediumEndocrinologyType 2 diabetes with cardiovascular diseaseau-amcau-racp
A 59-year-old man with type 2 diabetes and established atherosclerotic cardiovascular disease is taking metformin and a statin. HbA1c is 7.8% (62 mmol/mol). eGFR is 55 mL/min/1.73 m² and urinary albumin-creatinine ratio is elevated. According to contemporary Australian recommendations, which additional glucose-lowering agent is preferred to improve both glycaemic control and cardiovascular-renal outcomes?